Evidence map›Paper›PMID 37363403›Full record

ArticleFrontiers in molecular biosciences2023

Identification and validation of G protein-coupled receptors modulating flow-dependent signaling pathways in vascular endothelial cells.

Dike Qiu, Ke Xu, Namjin Chung, Jennifer Robbins, Robert Luo, Michael Lawrence, Aiqing He, Fei Yu, Andrew Alt, Michael M Miller and 4 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Adhesion G protein-coupled receptors.Pharmacological reviews · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Dike QiuResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Ke XuResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Namjin ChungResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Jennifer RobbinsResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Robert LuoResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Michael LawrenceResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Aiqing HeResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Fei YuResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Andrew AltResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Michael M MillerResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Jon HangelandResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
John N FederResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Dietmar SeiffertResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Brian J AreyResearch and Early Development, Bristol Myers Squibb Company, Princeton, NJ, United States.
Bristol-Myers Squibb (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vascular endothelial cells are exposed to mechanical forces due to their presence at the interface between the vessel wall and flowing blood. The patterns of these mechanical forces (laminar vs. turbulent) regulate endothelial cell function and play an important role in determining endothelial phenotype and ultimately cardiovascular health. One of the key transcriptional mediators of the positive effects of laminar flow patterns on endothelial cell phenotype is the zinc-finger transcription factor, krüppel-like factor 2 (KLF2). Given its importance in maintaining a healthy endothelium, we sought to identify endothelial regulators of the KLF2 transcriptional program as potential new therapeutic approaches to treating cardiovascular disease. Using an approach that utilized both bioinformatics and targeted gene knockdown, we identified endothelial GPCRs capable of modulating KLF2 expression. Genetic screening using siRNAs directed to these GPCRs identified 12 potential GPCR targets that could modulate the KLF2 program, including a subset capable of regulating flow-induced KLF2 expression in primary endothelial cells. Among these targets, we describe the ability of several GPCRs (GPR116, SSTR3, GPR101, LGR4) to affect KLF2 transcriptional activation. We also identify these targets as potential validated targets for the development of novel treatments targeting the endothelium. Finally, we highlight the initiation of drug discovery efforts for LGR4 and report the identification of the first known synthetic ligands to this receptor as a proof-of-concept for pathway-directed phenotypic screening to identify novel drug targets.

Indexed as

beta-arrestindrug discoveryendothelial cellsGPR101G protein coupled receptorKLF2laminar flowLGR4

Identifiers

PMID37363403
PMCPMC10285409
OpenAlexW4380050002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.